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Abstract
The dose-limiting side effect of the common colon cancer chemotherapeutic CPT-11 is severe
diarrhea caused by symbiotic bacterial β-glucuronidases that reactivate the drug in the gut. We
sought to target these enzymes without killing the commensal bacteria essential for human health.
Potent bacterial β-glucuronidase inhibitors were identified by high-throughput screening and
shown to have no effect on the orthologous mammalian enzyme. Crystal structures established
that selectivity was based on a loop unique to bacterial β-glucuronidases. Inhibitors were highly
effective against the enzyme target in living aerobic and anaerobic bacteria, but did not kill the
bacteria or harm mammalian cells. Finally, oral administration of an inhibitor protected mice from
CPT-11–induced toxicity. Thus, drugs may be designed to inhibit undesirable enzyme activities in
essential microbial symbiotes to enhance chemotherapeutic efficacy.
Camptothecin, a potent antineoplastic compound, was added to the National Cancer Institute
natural products screening set in 1966. It poisons the catalytic cycle of human topoisomerase
I, which manages the super-helical tension associated with DNA metabolism and is
preferentially active in rapidly dividing cells (1, 2). In preliminary clinical trials,
camptothecin exhibited marked toxicity and poor bioavailability (3). Although its
derivatives topotecan and CPT-11 (also called irinotecan) are now in clinical use (3), they
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still elicit pronounced side effects that limit efficacy. CPT-11 is one of the three commonly
used chemotherapeutic agents for colon cancer, and it has also been used against lung and
brain tumors as well as refractory forms of leukemia and lymphoma (4). It is a prodrug, with
a carbamate-linked dipiperidino group that increases solubility and bioavailability (3); this
moiety is removed in vivo to produce the active metabolite SN-38 (5) (Fig. 1A).
CPT-11 causes severe diarrhea generated by its complex activation and subsequent
metabolism (Fig. 1A) (6, 7). SN-38 produced by carboxylesterases is glucuronidated in the
liver by uridine diphosphate (UDP)–glucuronosyltransferase enzymes to form inactive
SN-38G (8), which is excreted via the biliary ducts into the gastrointestinal (GI) tract (Fig.
1A). Once in the intestines, though, SN-38G serves as a substrate for bacterial β-
glucuronidase enzymes in the commensal microbiota that remove the glucuronide group as a
carbon source, producing reactivated SN-38 in situ (Fig. 1A) (9, 10). SN-38 levels in the
intestinal lumen play an essential role in the delayed diarrhea that prevents dose
intensification and efficacy in up to 40% of treated patients (11–13).
The feasibility of using antibiotics to reduce GI bacteria levels prior to CPT-11 treatment
has been examined (14); however, this approach has several drawbacks. Intestinal biota play
essential roles in carbohydrate metabolism, vitamin production, and the processing of bile
acids, sterols, and xenobiotics (15, 16). Thus, the removal of GI bacteria is not
recommended for patients already challenged by neoplastic growths and chemotherapy. In
addition, elimination of symbiotic GI flora increases the chances of infections by pathogenic
bacteria, including enterohemorrhagic Escherichia coli and Clostridium difficile (17–23).
β-Glucuronidase enzymes hydrolyze glucuronic acid sugar moieties from a variety of
compounds (24), and their presence in a range of bacteria is exploited to detect bacterial
contamination in commonly used water purity tests (25). The crystal structure of human β-
glucuronidase was reported in 1996 (26), but no structure of a bacterial β-glucuronidase has
been presented. In addition, only relatively weak inhibitors of β-glucuronidases have been
described [inhibition constant (Ki) values of 25 μM to 2 mM] (27, 28). Thus, we used
structural and chemical biology to identify potent and selective inhibitors of bacterial β-
glucuronidases to eliminate the GI toxicity of CPT-11 without killing the bacterial
symbiotes required for intestinal health.
Full-length E. coli β-glucuronidase was purified and shown to hydrolyze SN-38G to SN-38
in vitro (fig. S1). The enzyme was initially crystallized both alone and in complex with an
established low-affinity inhibitor, glucaro-δ-lactam (GDL) (29), and data were collected to
2.5 and 2.4 Å resolution, respectively. Because molecular replacement using a previously
reported human β-glucuronidase model [PDB ID 1BHG (30)] was unsuccessful,
selenomethionine (SeMet)–substituted E. coli β-glucuronidase and single-wavelength
anomalous dispersion x-ray data to 2.9 Å resolution were used for structure determination
and refinement (PDB ID 3K4A). Molecular replacement using the SeMet model was then
used to determine and refine the native (PDB ID 3K46), GDL-bound (PDB ID 3K4D), and
Inhibitor 2 and Inhibitor 3 structures (PDB IDs 3LPF and 3LPG) (table S1).
The asymmetric unit of the E. coli β-glucuronidase structure contains two monomers of 597
ordered residues, and crystallographic symmetry generates the functionally relevant enzyme
tetramer observed previously for the human enzyme (30) and confirmed by gel filtration
chromatography for the E. coli form of the enzyme (Fig. 1B). The N-terminal 180 residues
resemble the sugar-binding domain of family 2 glycosyl hydrolases (31), whereas the C-
terminal domain (residues 274 to 603) forms an αβ barrel (31) and contains the active-site
residues Glu413 and Glu504. The region between the N- and C-terminal domains exhibits an
immunoglobulin-like β-sandwich domain consistent with other family 2 glycosyl hydrolases
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(31, 32) (fig. S2). The GDL inhibitor binds in a single orientation deep within the active site
of the enzyme’s C-terminal domain and involves large (>14 Å) shifts in residue positions
relative to the unliganded structure (figs. S3 and S4). Superimposing the E. coli β-
glucuronidase structure on the human enzyme reveals a 1.4 Å root mean square deviation
over 565 equivalent Cα positions with 45% sequence identity (figs. S5 and S6). The E. coli
enzyme contains a 17-residue “bacterial loop” not found in the human ortholog, with the
active site of each E. coli β-glucuronidase monomer containing “bacterial loops” from that
monomer as well as a neighboring monomer within the enzyme tetramer (fig. S4).
Chemical library screening was conducted using a β-glucuronidase assay in which the
conversion of 4-methylumbelliferyl-glucuronide (4-MUG) to 4-methylumbelliferone (4-
MU) was monitored by measuring the increase in 4-MU fluorescence (excitation at 365 nm,
emission at 450 nm) (fig. S7) (25). This assay exhibited robust characteristics when used
with a 10,240-compound chemical library, with a screening Z-factor of 0.84 (33). The hit
rate was 1%, with 100 compounds producing 90% inhibition or better and R2 values for
inhibition curves of 0.99 or better. Four compounds were chosen for further investigation
(Fig. 1C). Secondary β-glucuronidase assays were also used to examine inhibitor potency in
vitro and in cell-based studies.
The GDL compound exhibited relatively weak in vitro enzyme inhibition [e.g., median
inhibitory concentration (IC50) = 26.4 ± 4.83 μM] and did not disrupt β-glucuronidase
activity in cultured E. coli cells (fig. S8). In contrast, the four compounds chosen from the
high-throughput screen (Fig. 1C) were all potent in vitro inhibitors with submicromolar IC50
and Ki values and uncompetitive characteristics as assessed by their lack of impact on
enzyme kcat/Km values (Table 1 and fig. S9). Crystal structures of E. coli β-glucuronidase in
complexes with Inhibitors 2 and 3 were resolved to 2.3 and 2.4 Å resolution, respectively
(table S1), and revealed that the inhibitors bound at the “bacterial loops” at the entrance to
the active-site cavity, with the ethoxy groups extending to within 3.3 Å of the catalytic
Glu413 residue (Fig. 2A). Primary contacts between the enzyme monomer and inhibitors
involved the “bacterial loop” (Leu361) of the primary monomer, as well as the “bacterial
loop” (Phe365) of an adjacent monomer within the tetramer (Fig. 2B and fig. S10). Thus, this
loop may be essential to inhibitor efficacy.
The specificity of the four characterized inhibitors for bacterial versus mammalian β-
glucuronidases was assayed in vitro with the use of bovine liver β-glucuronidase. With a
concentration range of 0 to 100 μM for each of the inhibitors, no effect was observed on the
activity of this mammalian β-glucuronidase (figs. S11 and S12). The 17-residue loop that
contacts the inhibitors in the crystal structures of E. coli β-glucuronidase (Fig. 2, A and B) is
not present in mammalian forms of the enzyme (fig. S13), which act on larger substrates
such as glycosaminoglycans (34). Of the 284 GI-associated bacterial species in the Human
Microbiome Project database (35), 123 (43%) contained β-glucuronidases or candidate β-
glucuronidases; of those, 121 (98%) maintained at least the N-terminal portion of the
“bacterial loop,” and 110 (91%) contained the key residues at E. coli β-glucuronidase
positions 361 and 365 capable of making the inhibitor contacts reported here (fig. S14; see
also figs. S10 and S13 and table S2). To test the hypothesis that the “bacterial loop” is
required for the efficacy of our inhibitors, we created a form of E. coli β-glucuronidase that
lacks residues 360 to 376 (Fig. 3A). The Δ360-376 E. coli β-glucuronidase mutant was not
inhibited even at 100 μM concentrations of the four compounds examined (Fig. 3B). Thus,
we have identified inhibitors that are potent and selective for a bacterial β-glucuronidase.
We next examined the ability of the four lead compounds to inhibit β-glucuronidase activity
in living bacterial cells. Whereas a ~26 μM in vitro inhibitor such as GDL has no effect
against β-glucuronidase activity in cultured E. coli, each inhibitor tested was effective, with
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median effective concentration (EC50) values from 18 nM to 1.3 μM (Table 1 and fig. S15).
Because >99% of the microbial species present in the GI tract are obligate anaerobes (36),
we tested E. coli cells grown under anaerobic conditions and examined other relevant
anaerobic bacterial species (35). The compounds were effective in E. coli grown under both
aerobic and anaerobic conditions (Fig. 3C) and were effective against enzyme activity in
two obligate anaerobes known to inhabit the mammalian GI, Bacteroides vulgatus and
Clostridium ramosum (Fig. 3D). We also tested Lactobacillus reuteri and Bifidobacterium
infantis, which do not contain the gene encoding β-glucuronidase (28, 37), and found no
evidence of enzyme activity or inhibitor impact on cell viability for these or other strains
(figs. S16 and S17). Consistent with their lack of effect on mammalian β-glucuronidase
activity in vitro, inhibitors at relatively high concentrations (100 μM) had little to no effect
on the survival of two human colon cancer cell lines (HCT116, Caco-2) and one murine
colon cancer cell line (CMT93) (38) (fig. S18).
Finally, we examined the ability of Inhibitor 1 to eliminate the delayed diarrhea and
intestinal damage caused by CPT-11 administration. Healthy 6- to 8-week-old Balb/cJ mice
were divided into four groups of 16 animals each. Group 1 received 50 μl of double-distilled
H2O intraperitoneally (i.p.) and 1% dimethyl sulfoxide by oral gavage twice daily. Group 2
received 10 μg of Inhibitor 1 via oral gavage twice per day, but no CPT-11. Group 3
received CPT-11 i.p. once daily, at a dose of 50 mg per kg of body weight, and no Inhibitor
1. Group 4 received CPT-11 and Inhibitor 1 with dose and schedule identical to animals in
group 3 and group 2, respectively. GI symptoms appeared after 7 days. At days 8 to 10, all
the animals on the CPT-11–only treatment (group 3) experienced both diarrhea and bloody
diarrhea, whereas none of the animals receiving vehicle or inhibitor alone (groups 1 and 2,
respectively) exhibited diarrhea at any point during the study (Fig. 4A and fig. S19). By day
11, all the group 3 animals had to be euthanized. In contrast, the animals receiving both
CPT-11 and Inhibitor 1 (group 4), exhibited less diarrhea and bloody diarrhea than did the
group 3 animals (Fig. 4A and fig. S19). Examination and scoring of colonic tissue samples
from each group established that Inhibitor 1 protected the mouse GI epithelium from
CPT-11–induced damage (Fig. 4, B and C) (39). Animals treated with vehicle and Inhibitor
1 exhibited healthy glandular structure and an intact epithelial layer; CPT-11 administration
destroyed these tissues, eliminating the glands and causing a large influx of inflammatory
cells (Fig. 4, B and C). In contrast, Inhibitor 1, when provided orally in combination with
i.v. CPT-11, protected the glandular structure of these intestinal tissues (Fig. 4, B and C).
The lead compounds that we have characterized from high-throughput screening hits are all
effective inhibitors of the β-glucuronidase enzyme in vitro (with Ki values of 160, 210, 680,
and 1400 nM, respectively), and they maintain potent efficacy in living bacterial cells (EC50
values of 18, 28, 230, and 1300 nM, respectively) (Table 1) without affecting bacterial cell
growth or survival under aerobic or anaerobic conditions (figs. S16 and S17) or killing
mammalian epithelial cells (fig. S18). Lower EC50 values relative to the Ki values likely
reflect relatively low β-glucuronidase concentrations in cells. Key regions of the “bacterial
loop” identified in the E. coli β-glucuronidase crystal structure are present in 98% of the β-
glucuronidases sequenced from human GI bacteria, and 91% of those sequences contain
residues that appear capable of forming inhibitor contacts (figs. S13 and S14). Disruption of
β-glucuronidase activity is also demonstrated in bacterial species beyond E. coli (Fig. 3D).
Taken together, the data presented here strongly support the hypothesis that microbial β-
glucuronidases can be inhibited to prevent the GI production of toxic CPT-11 metabolites.
However, full pharmacokinetic studies demonstrating, for example, a reduction in GI
SN-38G levels or improved CPT-11 efficacy will be required to unambiguously prove this
hypothesis. In addition, the breadth of inhibitor efficacy on human GI bacteria requires
further assessment. Still, these initial results involving the oral dosing of an unmodified lead
compound are highly promising. If successfully translated to humans, leads like those
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described here could allow dose intensification of CPT-11, enabling studies of whether
efficacy could be improved in relevant human cancers by reducing one of the current dose-
limiting side effects. The strategy of selective targeting of an enzyme present in bacterial
symbiotes to address a specific clinical problem could potentially be applied more broadly
as we deepen our understanding of the essential and dynamic roles that commensal bacteria
play in promoting human health.
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CPT-11 metabolism and E. coli β-glucuronidase. (A) Intravenously administered CPT-11 is
activated by carboxylesterases (CE) to SN-38, an antineoplastic topoisomerase I poison.
Liver SN-38 is inactivated via glucuronidation to SN-38G by UDP-glucuronosyltransferase
(UGT) enzymes and sent to the intestines. β-Glucuronidases (β-glucs) in the symbiotic GI
bacteria remove the glucuronide as a carbon source, and active SN-38 in the intestinal lumen
generates dose-limiting diarrhea. (B) Crystal structure of the E. coli β-glucuronidase
tetramer at 2.5 Å resolution. (C) Four selective bacterial β-glucuronidase inhibitors
identified via high-throughput screening.
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Potent β-glucuronidase inhibitors. (A) Crystal structures of Inhibitors 2 and 3 bound to the
active site of E. coli β-glucuronidase. (B) Inhibitors are observed to stack cooperatively
between monomers in the E. coli β-glucuronidase tetramer. Amino acid abbreviations: D,
Asp; E, Glu; F, Phe; G, Gly; L, Leu; M, Met; R, Arg; S, Ser; Y, Tyr.
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Inhibitor selectivity for bacterial β-glucuronidase. (A) The 360–376 loop forms direct
contact with the bound inhibitors in the E. coli β-glucuronidase structure. This loop is
missing from the structure of human β-glucuronidase; thus, it is labeled the “bacterial loop.”
(B) Elimination of the “bacterial loop” from E. coli β-glucuronidase produces an enzyme
insensitive to inhibitor efficacy. (C) β-Glucuronidase inhibition in living E. coli cells grown
under both aerobic and anaerobic conditions. (D) β-Glucuronidase inhibition in two obligate
anaerobic bacteria. Error bars represent SD; N = 3.
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Alleviation of CPT-11 toxicity in mice. (A) CPT-11 produced bloody diarrhea starting after
8 days and peaking at 10 days, whereas oral administration of Inhibitor 1 with CPT-11
reduced the incidence of bloody diarrhea. Vehicle and Inhibitor 1 alone caused no bloody
diarrhea. By day 8 to 11, mice in the CPT-11 group began to suffer from severe lethargy and
lack of movement; by day 11, all mice in that group were euthanized according to AIC
protocol 20070715. (B) Histologic score of the distal and proximal colon of animals in the
four treatment groups. Error bars represent SD; N = 12. (C) Tissue histology of colons taken
from mice from each treatment group show healthy glandular structure for both vehicle and
Inhibitor 1 but highly disrupted tissues in the CPT-11 group. In contrast, Inhibitor 1
provided in combination with CPT-11 protects the colon from damage.
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Table 1
In vitro and bacterial cell–based assays for β-glucuronidase activity and inhibitor efficacy. kcat, catalytic rate;
Km, Michaelis constant; N/A, not applicable. N.E., not effective. Errors represent standard deviation, where N
= 3.
E. coli β-glucuronidase in vitro E. coli cell–based
IC50 (nM) kcat/Km (s−1 μM−1) Ki (nM) EC50 (nM)
No inhibitor N/A 0.134 ± 0.0123 N/A N/A
Glucaro-δ-lactam 26400 ± 483 N/A 7750 ± 475 N.E.
Inhibitor 1 283 ± 26.1 0.0987 ± 0.00621 164 ± 13.0 17.7 ± 7.42
Inhibitor 2 369 ± 2.51 0.119 ± 0.00473 208 ± 25.4 28.3 ± 2.11
Inhibitor 3 586 ± 31.1 0.136 ± 0.00633 684 ± 81.6 233.2 ± 2.99
Inhibitor 4 1060 ± 3.54 0.122 ± 0.0205 1380 ± 166 1322.8 ± 1.15
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